Electronic Data Capture (EDC) systems provider ClinCapture and biopharmaceutical firm MediciNova have formed a strategic collaboration aimed at Covid-19 research.
Last month, after the World Health Organization (WHO) confirmed more than 100,000 cases of global coronavirus cases, ClinCapture CEO Scott Weidley has expanded the philanthropic Weidley’s Wish programme, making it possible for those who are working on the advancement of Covid-19 research to freely access Captivate EDC.
Weidley’s Wish programme normally provides EDC to non-profit organisations, which are involved in conducting clinical trials of rare and orphan diseases.
Using Captivate EDC, companies receive the benefits of private cloud and modern user-interface (UI).
ClinCapture CEO Scott Weidley said: “We are excited to support MediciNova in this critical research. We are thankful that we were able to get this initiative started early, as awareness has grown dramatically.”
MediciNova will be using Captivate EDC to perform a clinical trial targeting severe Covid-19.
As part of plans to advance its research with the company’s investigational drug ibudilast (MN-166), MediciNova intends to target patients identified with acute respiratory distress syndrome (ARDS) associated with Covid-19.
Ibudilast is an oral, small-molecule inhibitor of macrophage migration inhibitory factor (MIF) and phosphodiesterase (PDE) -4 and -10. It inhibits pro-inflammatory cytokines and promotes neurotrophic factors.
In previous studies, the drug candidate led to a significant decrease in serum MIF level.
MediciNova president and CEO Yuichi Iwaki said: “We are very pleased to announce the initiation of a clinical trial of MN-166 in ARDS caused by Covid-19.”
The two companies will perform research using ClinCapture’s Captivate EDC.
Together, ClinCapture and MediciNova hope to advance medical research in finding a treatment for the prevention of acute respiratory distress syndrome.